Value Cases in development
Pharmacogenetics
In August 2023, the Innovation Design Authority (IDA) approved the Value Assessment to identify clopidogrel resistance in stroke patients and in February 2024 approved the change request to also implement pharmacogenetics to prevent gentamicin-induced hearing loss in new born babies.
A Value Case is now being developed to support these initiatives, with the potential to significantly improve patient outcomes across Scotland.
Diabetes Prevention
In October 2023, the IDA approved the Value Assessment for a digitally enabled programme designed to help individuals with prediabetes to reduce their weight and prevent the progression to type 2 diabetes.
A digital weight management and lifestyle programme, based on behaviour change methods, it will offer support from dietitians, nutritionists, and health coaches. Participants will engage in a 9-month programme aimed at achieving a 5% reduction in body weight. This reduction is expected to lead to lower BMI, blood pressure, and blood glucose levels, as well as increased physical activity and improved diet quality.
Chest X-Ray AI
in March 2024, the Innovation Design Authority approved the strategic case for implementing artificial intelligence (AI) to identify high-risk chest x-rays (CXRs).
The AI aims to flag high-risk CXR images in the lung cancer pathway, helping clinicians prioritise patients for CT scans. This could streamline diagnosis and treatment, improving patient outcomes.
Diabetes Remission
In August 2023, a Value Case was approved for implementing a digital diabetes remission programme aimed at supporting individuals living with type 2 diabetes to reduce their weight and achieve remission.
The current implementation is pending approval by the Scottish Government. The programme will enrol people newly diagnosed with type 2 diabetes into an intensive weight management programme. This programme, led by specialist dietitians and health coaches, will be delivered via a fully remote digital healthcare platform.